As of 2023, the sales of nervous system medicines in the UK stood at 3.40 billion pounds sterling. Forecasts indicate a modest year-on-year growth: 2024 (0.88%), 2025 (0.87%), 2026 (0.87%), 2027 (1.15%), and 2028 (0.84%). The compound annual growth rate (CAGR) over these five years is approximately 0.92%, suggesting consistent market expansion for this sector.
Future trends to watch for include advancements in neurotechnology and personalized medicine, increased prevalence of neurological disorders due to an aging population, and potential impacts of healthcare policies and economic factors on drug accessibility and pricing.
